fondaparinux sodium
PreclinicalSmall molecule
GSKfondaparinux sodium is a small molecule that works as Antithrombin-III Activator.[2] It is being investigated across 9 indications, with its most advanced program in Preclinical.[1]
fondaparinux sodium is one of 201 small molecule programs targeting Intermediate Coronary Syndrome. It is currently in Preclinical.
9
Indications
19
Total Trials
1
Active Trials
200
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Coreg
Akero TherapeuticsApproved
Calan
VVal Adams
Approved
Foradil
ViatrisApproved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Cagrilintide
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Venous Thromboembolism2 trials
Thromboembolism2 trials
Knee Injury1 trial
Percutaneous Coronary Intervention (PCI)1 trial
12 more indications
Kidney Failure1 trial
Major Abdominal Surgery1 trial
Myocardial Infarction1 trial
Thrombophlebitis1 trial
Medication1 trial
Deep Vein Thrombosis1 trial
Drug1 trial
General Surgery1 trial
Abdominal Surgery1 trial
Function1 trial
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Completed·—·Phase 1·NCT01121770·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for fondaparinux sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]